Molecular oncology of lung cancer

被引：55

作者：

Toyooka S. ^{[1
]}

Mitsudomi T. ^{[2
]}

Soh J. ^{[1
]}

Aokage K. ^{[1
]}

Yamane M. ^{[1
]}

Oto T. ^{[1
]}

Kiura K. ^{[3
]}

Miyoshi S. ^{[1
]}

机构：

[1] Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558

[2] Department of Thoracic Surgery, Aichi Cancer Center, Nagoya

[3] Department of Hematology Oncology, Allergy and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama

来源：

General Thoracic and Cardiovascular Surgery | 2011年 / 59卷 / 8期

关键词：

Biology; Lung cancer; Molecular oncology;

D O I：

10.1007/s11748-010-0743-3

中图分类号：

学科分类号：

摘要：

Progress in genetic engineering has made it possible to elucidate the molecular biological abnormalities in lung cancer. Mutations in KRAS and P53 genes, loss of specific alleles, and DNA methylation of the tumor suppressor genes were the major abnormalities investigated between 1980 and the 2000s. In 2004, mutations in the epidermal growth factor receptor (EGFR) gene that cause oncogene addiction were discovered in non-small-cell lung cancers (NSCLCs), especially in adenocarcinomas. Because they are strongly associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), a great deal of knowledge has been acquired in regard to both EGFR and other genes in the EGFR family and their downstream genes. Moreover, in 2007 the existence of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene was discovered in NSCLC; and the same as EGFR-TKIs, ALK inhibitors are being found to be highly effective in lung cancers that have this translocation. These discoveries graphically illustrate that molecular biological findings are directly linked to the development of clinical oncology and to improving the survival rates of lung cancer patients. Here, we review the remarkable progress in molecular biological knowledge acquired thus far in regard to lung cancer, especially NSCLC, and the future possibilities. © 2011 The Japanese Association for Thoracic Surgery.

引用

页码：527 / 537

页数：10

共 93 条

[1]

Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J., Cancer statistics, 2009, CA Cancer J Clin, 59, pp. 225-249, (2009)

[2]

Fukui T., Mitsudomi T., Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers, General Thoracic and Cardiovascular Surgery, 56, 3, pp. 97-103, (2008)

[3]

Jida M., Toyooka S., Mitsudomi T., Takano T., Matsuo K., Hotta K., Et al., Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment, Cancer Sci, 100, pp. 1931-1934, (2009)

[4]

Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, New England Journal of Medicine, 355, 24, pp. 2542-2550, (2006)

[5]

Yarden Y., The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities, Eur J Cancer, 4, (2001)

[6]

Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M., EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy, Science, 304, 5676, pp. 1497-1500, (2004)

[7]

Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, 350, 21, pp. 2129-2139, (2004)

[8]

Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., Fong K.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J.A., Herz J., Minna J.D., Gazdar A.F., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, Journal of the National Cancer Institute, 97, 5, pp. 339-346, (2005)

[9]

Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, New England Journal of Medicine, 352, 8, pp. 786-792, (2005)

[10]

Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Medicine, 2, 3, pp. 0225-0235, (2005)

← 1 2 3 4 5 6 7 8 9 10 →